The Point Tile

The Point Blog ARCHIVE
All articles found in the archive are more than three years old.

 

The purpose of this blog is to stimulate thought and discussion about important issues in healthcare. Opinions expressed are those of the author and do not necessarily express the views of CMDA. We encourage you to join the conversation on our website and share your experience, insight and expertise. CMDA has a rigorous and representative process in formulating official positions, which are largely limited to bioethical areas.

Gene Editing to Make Better Human Beings?

September 14, 2017

by David Prentice, PhD

“I mean, if we could make better human beings by knowing how to add genes, why shouldn’t we do it?”
—Nobel Laureate James Watson, 1998

“Soon it will be a sin for parents to have a child that carries the heavy burden of genetic disease. We are entering a world where we have to consider the quality of our children.”
— Embryologist Robert Edwards, 1999

Gene editing (the current term of art for genetic engineering or genome manipulation) has potential for great benefit but also for great evil. In the medical realm, great advances are possible, treating individuals with genetic diseases, intractable cancers and previously incurable diseases, as well as designing new drugs. But this dual-use technology also could be used to design children, weaponize biological agents or even alter or dehumanize our concept of humanity. As with many cutting-edge biological technologies, much depends on the targets, attitudes and motivations of the innovators.

Genetic engineering is a hot research topic again, due primarily to the development of more accurate enzyme systems, including CRISPR-Cas, that can target the cutting and splicing of DNA with a precision not seen previously. Though still not 100 percent accurate, these new tools have fueled attempts to cut and paste specific gene sequences at targeted sites within the genome. Trials have already begun to modify the genes of people affected with genetic diseases or to treat cancer patients using genetically-altered immune cells. These gene editing projects are worthwhile pursuits, not least because they target alleviating the conditions of existing individuals.

However, there have also been ethically troubling attempts to alter the genomes of human embryos. This “germline” gene editing is aimed at creating new individuals with altered DNA, with the modified genome able to be passed on to future generations, along with unknown consequences for the gene-manipulated individual and future generations. Over the last two years, Chinese researchers have published three reports on their use of gene editing tools on human embryos. Now a U.S. researcher has reported a gene editing experiment on normal human embryos, including statements on his desire to gestate and birth some of these gene-edited children. Perhaps unsurprising, this researcher (Shoukhrat Mitalipov, PhD) is also the one who created cloned human embryos, created three-parent human embryos using cloning techniques and advocated for gestation and birth of three-parent embryos.

In this recent gene editing experiment on human embryos, the researchers were attempting to create embryos with correction of a mutation that causes hypertrophic cardiomyopathy. Their results, they claim, show their technique is safe and effective for genetic engineering of embryos. They injected the gene editing enzyme and template (the nucleic acid sequence used to produce “corrected” DNA sequence) into an egg along with a sperm, so that the germline gene editing occurred as the new embryo was conceived. In a series of experiments varying when the enzyme was injected, the scientists created 142 human embryos; all were subsequently destroyed. The results reported by the team were almost too good to be true and certainly much less than safe and effective. The mutation reportedly was corrected in 72 percent of gene-edited embryos, with no off-target snipping of DNA (sometimes the enzyme clips or mutates other spots in the DNA because it is not 100 percent accurate.) However, the numbers only indicate no off-target cutting for the sites checked by the team, which was not exhaustive and likely missed some unintended mutations. The researchers also reported that their injected template was not used for correcting the DNA; they suggest this may be due to a novel mechanism in early embryos, but it also suggests problems in the experimental design and interpretation. The data also suggest that in some cases the mutation was not corrected, but rather a large section of DNA deleted.

Other researchers have since published a paper online that calls into question the conclusions of the Mitalipov gene editing paper, noting the mechanism is biologically improbable and alternative explanations are likely. But whether the gene editing results are invalid in this experiment, there is a continued push by some scientists to do human embryo experiments. Korean scientists recently urged their government to relax restrictions on human embryo experiments, while scientists in the U.K. and Sweden have been approved to begin gene editing experiments on human embryos. Dr. Mitalipov himself encouraged others to do gene editing experiments on human embryos, and he has stated his hope that U.S. lawmakers would loosen restrictions currently in place that prohibit funding of such experiments as well as clinical trials placing gene-edited embryos in the womb.

There is still time to slow this headlong rush to perfect the quality of our children and make “better” human beings, time to change the trajectory of the science away from human embryos to the human patients who need the medical advances. In the movie Gattaca, the main character struggles to overcome the stigma of not being genetically designed and enhanced (a “valid” birth), as well as overcome the genetic caste system that gene editing of human embryos would create. Scientists who want to be the first to successfully modify human embryos should not be the only voices in the debate. Patients and their advocates should also be heard, especially on the question of whether we should engineer our children.

David Prentice, PhD

David Prentice, PhD

David A. Prentice is Vice President and Research Director for the Charlotte Lozier Institute. He is also Adjunct Professor of Molecular Genetics at the John Paul II Institute, The Catholic University of America and was a Founding Advisory Board Member for the Midwest Stem Cell Therapy Center, a unique comprehensive stem cell center in Kansas that he was instrumental in creating. In 2020, he was appointed by the Secretary of HHS to the federal Human Fetal Tissue Ethics Advisory Board. Dr. Prentice has over 40 years’ experience as a scientific researcher and professor, including previous service as senior fellow for life sciences at the Family Research Council, Professor of Life Sciences at Indiana State University, and Adjunct Professor of Medical and Molecular Genetics, Indiana University School of Medicine.

He established Stem Cell Research Facts, an educational website providing scientific facts and patient-centered videos about adult stem cells, and is a founding member of Do No Harm: The Coalition of Americans for Research Ethics, and an advisory board member for the Center for Bioethics and Human Dignity. He has provided scientific advice for numerous medical professionals, legislators, policymakers and organizations at the state, federal, and international levels.

Dr. Prentice received his Ph.D. in biochemistry from the University of Kansas, and was at Los Alamos National Laboratory and the University of Texas Medical School-Houston before joining Indiana State University where in addition to his research and teaching, he served as Acting Associate Dean of Arts and Sciences and Assistant Chair of Life Sciences. He was recognized with the University’s Caleb Mills Distinguished Teaching Award and Faculty Distinguished Service Award. He has taught courses ranging from non-majors biology to advanced and graduate courses including developmental biology, embryology, cell and tissue culture, history of biology, science and politics, pathophysiology, medical genetics, and medical biochemistry. Several of his courses were also taught on-line.

He received the 2007 Walter C. Randall Award in Biomedical Ethics from the American Physiological Society, given for promoting the honor and integrity of biomedical science through example and mentoring in the classroom and laboratory. Dr. Prentice’s research interests encompass various aspects of cell growth control, cell and developmental biology; one major focus is adult stem cells. He has reviewed for various professional publications including The Journal of the American Medical Association.

He is an internationally-recognized expert on stem cell research, cell biology and bioethics, and has provided scientific lectures and policy briefings in 40 states and 21 countries, including testimony before the U.S. Congress and numerous state legislatures, the U.S. National Academy of Sciences, the President’s Council on Bioethics, European Parliament, British Parliament, Canadian Parliament, Australian Parliament, German Bundestag, French Senate, Swedish Parliament, the United Nations, and the Vatican. He was selected by President George W. Bush’s U.S. President’s Council on Bioethics to write the comprehensive review of adult stem cell research for the Council’s 2004 publication “Monitoring Stem Cell Research.”

Dr. Prentice has published numerous scientific and bioethics articles, including a recent review of stem cell science and adult stem cell treatments published in Circulation Research. He has also published numerous commentaries and op-eds, and travels nationally and internationally to give frequent invited lectures regarding stem cell research, fetal tissue research, gene editing, cloning, embryology, cell culture and vaccines, bioethics, and public policy. He has been interviewed in virtually all major electronic and print media outlets, including CNN, ABC, NBC, CBS, Fox, CSPAN, Reuters, AP, NPR, USA Today, BBC, The Washington Post, The Los Angeles Times, and The New York Times.